Live cellular imaging without incisions

Where live imaging and deep data meet.

Enspectra Health is pioneering a new field of virtual biopsies to transform the way physicians evaluate a broad spectrum of skin conditions. 


Our novel technology combines reflectance confocal and multiphoton laser scanning microscopy to generate real-time, multispectral images spanning wavelengths not seen with the naked eye. The unique integration of these technologies produces images with increased depth, greater cellular detail, and more distinctive color contrast.


Our platform technology delivers pulsed near-infrared light through the skin’s surface, providing high-resolution images at the cellular level, without the need for an incision. The technology allows for an instantaneous evaluation of rich, digital pathology images of various skin tissues, potentially enabling earlier and less costly interventions.

AI Face of Woman_Final.jpg

Enspectra Health is developing a device targeted at dermatologists to aid in the evaluation of a variety of skin conditions including nonmelanoma skin cancers (NMSCs).


Leveraging our novel platform technology, high-resolution, cellular images of the skin are produced noninvasively.  


By arming clinicians with rich skin tissue images, we hope to aid in more informed decision making, with the ultimate goal of minimizing unnecessary biopsies, leading to earlier disease diagnosis and interventions. 

"Our mission is to develop and deploy technologies focused on earlier disease detection, leveraging revolutionary imaging and machine learning, in order to transform patient care."

 - Gabriel Sanchez, CEO Enspectra Health

Cut Out Unnecessary Biopsies




CoFounder & CEO

Leveraging his extensive experience innovating in the fields of optics and electromechanical devices, Gabriel serves as the visionary for Enspectra Health. Working with a team of experts, Gabriel is leading the rapid advancement and development of Enspectra's multiphoton imaging device to evaluate a broad spectrum of skin conditions. 


President & COO

Bill has over 20 years of experience in medical device executive management, operations, manufacturing, supply chain, and infrastructure. He has supported product launches and scale up activities at several device startups, leading to acquisitions by companies such as Hologic, Medtronic and Stryker Corporation. 


Clinical & Market Development Manager

Kate has extensive research experience developing novel methods and experimental techniques for optical bioinstrumentation. Leveraging her expertise, Kate is leading the product and clinical trial design for Enspectra's device which evaluates a variety of skin conditions including nonmelanoma skin cancers (NMSCs). 


Director of Systems Engineering

Mark has over a decade of experience advising and designing novel technologies for several device companies. Mark brings a wealth of knowledge in the areas of hardware, electrical and firmware engineering, rapid prototyping, and supply chain optimization. 



Mark is a professor of biology and applied physics at Stanford University who has pioneered microendoscopy for in vivo imaging.  An expert in the custom design of optical instrumentation and multiphoton imaging techniques, his research at Stanford has spawned multiple scientific breakthroughs. 


CoFounder & Director

Scott is the Director of the Stanford Neuromuscular Biomechanics Laboratory. He has cofounded several companies, including Musculographics (now Motion Analysis Corp), Surgical Graphics (acquired by Medtronic), Cala Health, Enspectra Health, and Circuit Therapeutics. 

Texture #1.jpg



Enspectra Receives Series A Funding; Moves Forward in Widening Market for Skin Cancer Detection Breakthrough

A $2 Million Grant From the National Cancer Institute A Highlight of a Noteworthy Year for Enspectra Health

Meet Gabriel Sanchez, CEO of Enspectra Health




2495 Hospital Drive, Suite 300
Mountain View, CA  94040

(650) 480-6022


Follow our progress.

© 2021 Enspectra Health, Inc. All Rights Reserved.

CAUTION: The Enspectra Health device is currently undergoing pre-clinical investigations and is not available for human use.